Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data

This time it's Incyte Corporation, a $5.5 billion market cap company that just enjoyed a more than $10 rise in its share price to over $37/share after positive data was announced for its mid-phase pancreatic cancer clinical trials.

http://www.freshnews.com/news/837467/nuvilex-investors-watch-incyte-shares-rise-sharply-pancreatic-cancer-trials-data-